Deborah K. Armstrong

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 19 papers. Top paper: “Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade”.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Science(2017)10.1126/science.aan6733

N/A

1.3DataRank · unranked

6550 citations

Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne R. Bartlett, Laveet K. Aulakh +46 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

JCO Precision Oncology(2024)10.1200/po.24.00254

N/A

0.284DataRank · unranked

5 citations

Jaime Wehr, Katerina Karaindrou, Rena R. Xian, Christopher D. Gocke, Ming‐Tseh Lin +35 more

A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5574

N/A

0.241DataRank · unranked

4 citations

Mary Wilkinson, Lainie P. Martin, Amy Deery, Amanda Langsdale, Asnakech Bayable +6 more

The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07611-y

N/A

0.104DataRank · unranked

1 citations

Zhengyi Deng, Michelle S. McCullough, Betty J. May, Erica Selznick, Jennifer Y. Sheng +4 more

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.08.024

N/A

0DataRank · unranked

117 citations

Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin +17 more

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.12.007

N/A

0DataRank · unranked

15 citations

Neha Mangini, John H. Fetting, Deborah K. Armstrong, Isaac S. Chan, Roisín M. Connolly +13 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

npj Breast Cancer(2022)10.1038/s41523-022-00414-0

N/A

0DataRank · unranked

28 citations

Neha Verma, Amanda L. Blackford, Jennifer Lehman, Kelly Westbrook, David K. Lim +15 more

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2444

N/A

0DataRank · unranked

79 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.11.020

N/A

0DataRank · unranked

0 citations

Bhavana Pothuri, Karen A. Cadoo, Yvette Drew, Rachel Miller-Garcia, Deborah K. Armstrong +2 more

Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

10.1158/1078-0432.23814207.v1

N/A

0DataRank · unranked

0 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer

10.1158/1078-0432.27031096

N/A

0DataRank · unranked

0 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

10.1158/1078-0432.23518857.v1

N/A

0DataRank · unranked

0 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.19.02960

N/A

0DataRank · unranked

383 citations

Barbara M. Norquist, Christina Lacchetti, Deborah K. Armstrong, Rachel N. Grisham, Paul J. Goodfellow +7 more

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

Obstetrical & Gynecological Survey(2020)10.1097/ogx.0000000000000777

N/A

0DataRank · unranked

6 citations

Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong +19 more

Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status

UNC Libraries(2020)10.17615/6wxj-0g75

N/A

0DataRank · unranked

0 citations

Claudine Isaacs, Patrick M. Sluss, Phuong Mai, Wendy R. Brewster, Gustavo C. Rodriguez +25 more

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials

UNC Libraries(2020)10.17615/2xde-se42

N/A

0DataRank · unranked

0 citations

Phuong L. Mai, David S. Alberts, William J. Welch, Carol J. Fabian, Mary B. Daly +32 more